Free tool
FAERS Monitor: Nasacort Allergy 24 Hour
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020468 or its brand name (Nasacort Allergy 24 Hour, Triamcinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
29,292
Serious
13,599
46% of reports
Hospitalization
6,385
Death reported
3,180
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective5,253
- off label use2,925
- pruritus2,760
- rash2,607
- pain2,187
- fatigue2,113
- nausea2,038
- headache1,872
- condition aggravated1,798
- diarrhoea1,763
- product use in unapproved indication1,763
- vomiting1,741
- dizziness1,587
- arthralgia1,576
- malaise1,424
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 71 |
| 2005 | 58 |
| 2006 | 40 |
| 2007 | 80 |
| 2008 | 116 |
| 2009 | 110 |
| 2010 | 113 |
| 2011 | 177 |
| 2012 | 175 |
| 2013 | 203 |
| 2014 | 253 |
| 2015 | 2,003 |
| 2016 | 1,396 |
| 2017 | 1,355 |
| 2018 | 1,687 |
| 2019 | 1,455 |
| 2020 | 1,650 |
| 2021 | 1,913 |
| 2022 | 2,445 |
| 2023 | 2,871 |
| 2024 | 3,654 |
| 2025 | 4,065 |
| 2026 | 3,402 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,024,867 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pruritusSignal | 2,760 | 5.2 | 5.0 | 9,429 |
| product use in unapproved indicationSignal | 1,763 | 5.1 | 4.9 | 5,898 |
| rashSignal | 2,607 | 4.3 | 4.2 | 6,734 |
| condition aggravatedSignal | 1,798 | 4.3 | 4.1 | 4,531 |
| drug ineffectiveSignal | 5,253 | 2.9 | 2.8 | 6,796 |
| arthralgiaSignal | 1,576 | 2.7 | 2.6 | 1,752 |
| vomitingSignal | 1,741 | 2.7 | 2.5 | 1,844 |
| painSignal | 2,187 | 2.6 | 2.5 | 2,136 |
| off label useSignal | 2,925 | 2.4 | 2.3 | 2,491 |
| malaiseSignal | 1,424 | 2.3 | 2.2 | 1,106 |
| dizzinessSignal | 1,587 | 2.3 | 2.2 | 1,175 |
| headacheSignal | 1,872 | 2.1 | 2.1 | 1,178 |
| diarrhoea | 1,763 | 2.0 | 1.9 | 857 |
| fatigue | 2,113 | 2.0 | 1.9 | 1,014 |
| nausea | 2,038 | 1.9 | 1.8 | 826 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.